LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC) Files An 8-K Results of Operations and Financial Condition
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
release announcing its financial results for the three months
ended March 31, 2017. A copy of the press release is furnished as
Exhibit 99.1. The press release should be read in conjunction
with the note regarding forward looking statements, which is
included in the text of the press release.
treated as “filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that section. This
information will not be incorporated by reference into any filing
under the Securities Act of 1933, as amended, or into another
filing under the Exchange Act, unless that filing expressly
incorporates this information by reference.
report on Form 8-K:
|
Exhibit
No.
|
Description
|
|
|
99.1
|
Earnings Press Release dated April 27, 2017.
|
About LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC)
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products. Its product candidates in development include LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb. The Company is developing LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH). The Company is developing LJPC-401 for the treatment of iron overload, which occurs as a result of diseases, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. It is developing LJPC-30Sa and LJPC-30Sb not only for the treatment of serious bacterial infections but also for the potential treatment of rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC) Recent Trading Information
LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC) closed its last trading session up +0.23 at 29.23 with 619,714 shares trading hands.
